Alzheimer’s research is shifting toward precision medicine, and Lighthouse Pharmaceuticals is leaning in hard. The company will present new clinical insights at CTAD 2025 in San Diego on December 3, 2025.
Their poster, titled “The SPRING Trial: Treatment of P. gingivalis–Positive Mild to Moderate Alzheimer’s Disease with the Second-Generation Gingipain Inhibitor LHP588,” highlights the science behind one of the most closely watched trials in the field.
Why This Presentation Matters?
Lighthouse is targeting a bacterial driver of Alzheimer’s disease: P. gingivalis.
This approach has gained momentum after early studies showed meaningful impact on cognitive decline.
The National Institute on Aging (NIA) recently awarded the company $49.2 million to fund the SPRING trial. That level of support signals confidence in this mechanism and in Lighthouse’s strategy.
What the SPRING Trial Is Built On?
The SPRING study is designed for people with P. gingivalis–positive mild to moderate Alzheimer’s disease. It follows encouraging results from the earlier GAIN trial, which showed that gingipain inhibition slowed cognitive decline in selected patients.
Key Highlights
- SPRING is a Phase 2 trial evaluating LHP588.
- It uses biomarker-guided patient selection to maximize treatment benefit.
- The trial expands on mechanistic and safety learnings from the GAIN study.
- The NIA’s $49.2 million award validates the scientific foundation.
Meet LHP588: A Second-Generation Precision Drug
LHP588 was engineered to overcome limitations of the earlier molecule, atuzaginstat.
It offers improved safety, stronger target engagement, and once-daily oral dosing.
According to Chief Medical Officer Michael Detke, LHP588 represents “a significant advancement in targeting a bacterial driver of Alzheimer’s disease with a high-precision oral medication.”
He emphasized that focusing on P. gingivalis–positive patients may unlock meaningful clinical benefit for a population with no disease-modifying options. Lighthouse expects to expand enrollment across the United States in 2026.
About Lighthouse Pharmaceuticals
Lighthouse develops small-molecule therapies for chronic degenerative and inflammatory diseases. Its lead program focuses on Alzheimer’s disease, supported by deep translational science and clinical expertise.
Research for the SPRING trial is funded by the National Institute on Aging under Award Number R01AG088524.
